Profile data is unavailable for this security.
About the company
Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company focused on developing immunotherapeutic candidates for treating autoimmune and inflammatory diseases. The Company’s pipeline, built around platform technologies; viral vector-based, consists of ChAdOx and MVA, and synthetic, consisting of SNAP-Tolerance Immunotherapy (SNAP-TI). These platforms help to develop antigen-specific immunotherapeutic candidates designed to optimize the disease fighting capabilities of T cells. It is focused on developing two product candidates that harness its viral vector and synthetic platform technologies. These include VTP-300, a Phase II immunotherapeutic candidate designed as a potential component of a functional cure for chronic hepatitis B virus infection utilizing ChAdOx/MVA, and VTP-1000, its autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease. The Company's pipeline also includes VTP-850, VTP-500 and VTP-400.
- Revenue in USD (TTM)0.00
- Net income in USD-75.88m
- Incorporated2021
- Employees105.00
- LocationBarinthus Biotherapeutics PLCThe Schrdinger BuildingHeatley Road, The Oxford Science ParkDIDCOT OX11 0DFUnited KingdomGBR
- Phone+44 186 581 8808
- Websitehttps://www.barinthusbio.com/
More ▼
Mergers & acquisitions
| Acquired company | 2AB:FRA since announced | Transaction value |
|---|---|---|
| Clywedog Therapeutics Inc | -50.51% | -- |
Data delayed at least 15 minutes, as of Mar 05 2026 07:02 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apollomics Inc | 8.50m | -31.19m | 22.63m | 13.00 | -- | -- | -- | 2.66 | -26.61 | -26.61 | 8.01 | -3.99 | 0.3721 | -- | -- | 653,846.10 | -136.51 | -- | -276.35 | -- | -- | -- | -366.92 | -- | -- | -- | -- | -- | -- | -- | 68.80 | -- | -- | -- |
| Exicure Inc | 0.00 | -9.23m | 22.75m | 8.00 | -- | 3.28 | -- | -- | -3.07 | -3.07 | 0.00 | 1.09 | 0.00 | -- | -- | 0.00 | -71.27 | -44.45 | -94.78 | -60.08 | -- | -- | -- | -259.52 | -- | -- | 0.00 | -- | -- | -17.34 | 42.65 | -- | -- | -- |
| Linike Medical Group Ltd | 0.00 | -306.90k | 23.41m | -- | -- | -- | -- | -- | -0.1102 | -0.1102 | 0.00 | -0.153 | 0.00 | -- | -- | -- | -278.62 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -651.26 | -- | -- | -- |
| Skye Bioscience Inc | 0.00 | -51.23m | 23.74m | 16.00 | -- | 0.6989 | -- | -- | -1.29 | -1.29 | 0.00 | 1.06 | 0.00 | -- | -- | 0.00 | -83.39 | -139.20 | -94.11 | -262.81 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 29.43 | -- | -- | -- |
| Cue Biopharma Inc | 7.10m | -37.68m | 23.80m | 41.00 | -- | 1.78 | -- | 3.35 | -0.4553 | -0.4553 | 0.0823 | 0.1703 | 0.1857 | -- | 4.01 | 173,170.70 | -98.58 | -60.20 | -170.74 | -73.56 | -- | -- | -530.75 | -683.99 | -- | -- | 0.1107 | -- | 69.16 | 21.84 | 19.83 | -- | 7.32 | -- |
| IO Biotech Inc | 0.00 | -88.35m | 23.87m | 80.00 | -- | 25.38 | -- | -- | -1.34 | -1.34 | 0.00 | 0.0131 | 0.00 | -- | -- | 0.00 | -136.03 | -58.51 | -184.96 | -64.76 | -- | -- | -- | -- | -- | -- | 0.9482 | -- | -- | -- | -10.93 | -- | -- | -- |
| Vistagen Therapeutics Inc | 805.00k | -67.05m | 23.97m | 59.00 | -- | 0.4707 | -- | 29.78 | -1.90 | -1.90 | 0.0228 | 1.29 | 0.0102 | -- | -- | 14,375.00 | -85.21 | -55.19 | -99.91 | -59.56 | -- | -- | -8,328.70 | -5,842.62 | -- | -- | 0.0074 | -- | -54.32 | -- | -75.12 | -- | -- | -- |
| Marker Therapeutics Inc | 4.69m | -14.30m | 24.01m | 5.00 | -- | 1.31 | -- | 5.11 | -1.23 | -1.23 | 0.3683 | 1.10 | 0.2876 | -- | 3.90 | 938,996.00 | -87.60 | -57.72 | -110.67 | -69.11 | -- | -- | -304.54 | -761.28 | -- | -- | 0.00 | -- | 99.06 | 98.63 | 23.60 | -- | -- | -- |
| Barinthus Biotherapeutics PLC - ADR | 0.00 | -75.88m | 24.50m | 105.00 | -- | 0.29 | -- | -- | -1.88 | -1.88 | 0.00 | 2.07 | 0.00 | -- | -- | 0.00 | -50.99 | -21.90 | -55.89 | -23.34 | -- | -- | -- | -302.54 | -- | -- | 0.00 | -- | 1,766.46 | 16.94 | 16.73 | -- | 47.49 | -- |
| Evaxion A/S (ADR) | 7.65m | -5.42m | 24.64m | 46.00 | -- | -- | -- | 3.22 | -16.88 | -16.88 | 2.18 | -- | -- | -- | -- | 166,326.10 | -- | -96.54 | -- | -126.06 | -- | -- | -70.88 | -2,792.25 | -- | -- | -- | -- | 4,480.82 | -- | 52.24 | -- | -- | -- |
| Neuphoria Therapeutics Inc | 15.00m | -5.66m | 25.01m | 7.00 | -- | 0.8401 | -- | 1.67 | -2.12 | -2.12 | 5.77 | 5.52 | 0.5478 | -- | 26.19 | 2,142,857.00 | -20.68 | -35.39 | -22.63 | -39.01 | -- | -- | -37.76 | -375.66 | -- | -4.22 | 0.0011 | -- | -- | 246.65 | 97.61 | -- | -- | -- |
| Senti Biosciences Inc | 0.00 | -47.58m | 25.04m | 34.00 | -- | 3.08 | -- | -- | -2.80 | -2.80 | 0.00 | 0.3089 | 0.00 | -- | -- | 0.00 | -86.19 | -50.97 | -106.55 | -57.59 | -- | -- | -- | -2,565.78 | -- | -- | 0.00 | -- | -100.00 | -- | 36.71 | -- | -58.03 | -- |
| Fibrobiologics Inc | 0.00 | -18.65m | 25.40m | 15.00 | -- | 4.06 | -- | -- | -0.444 | -0.444 | 0.00 | 0.0925 | 0.00 | -- | -- | 0.00 | -143.08 | -- | -322.07 | -- | -- | -- | -- | -- | -- | -12.08 | 0.00 | -- | -- | -- | -67.06 | -- | -- | -- |
| Boundless Bio Inc | 0.00 | -61.76m | 25.52m | 64.00 | -- | 0.2316 | -- | -- | -16.06 | -16.06 | 0.00 | 4.92 | 0.00 | -- | -- | 0.00 | -35.93 | -- | -38.37 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -32.22 | -- | -- | -- |
| Axe Compute Inc | 728.20k | -84.01m | 26.38m | 23.00 | -- | -- | -- | 36.22 | -120.02 | -120.66 | 1.29 | -100.94 | 0.1369 | 1.34 | 2.97 | 31,660.87 | -1,579.84 | -85.09 | -- | -113.42 | 50.24 | 61.31 | -11,536.93 | -1,267.27 | 0.0134 | -0.1392 | -- | -- | -0.2384 | 2.84 | 9.63 | -- | -18.60 | -- |
| Passage Bio Inc | 0.00 | -45.26m | 27.07m | 60.00 | -- | 0.8621 | -- | -- | -14.47 | -14.47 | 0.00 | 9.79 | 0.00 | -- | -- | 0.00 | -48.69 | -49.32 | -61.70 | -53.58 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 36.54 | -- | -54.23 | -- |
Data as of Mar 05 2026. Currency figures normalised to Barinthus Biotherapeutics PLC's reporting currency: US Dollar USD
15.86%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| M&G Investment Management Ltd.as of 31 Dec 2025 | 5.20m | 12.73% |
| DC Investments Management LLCas of 31 Dec 2025 | 642.20k | 1.57% |
| Renaissance Technologies LLCas of 31 Dec 2025 | 143.10k | 0.35% |
| The Johns Hopkins University (Investment Management)as of 31 Dec 2025 | 122.24k | 0.30% |
| Citadel Securities LLCas of 31 Dec 2025 | 118.80k | 0.29% |
| Robert W. Baird & Co., Inc. (Private Banking)as of 31 Dec 2025 | 105.96k | 0.26% |
| Rangeley Capital LLCas of 31 Dec 2025 | 84.44k | 0.21% |
| Hightower Advisors LLCas of 31 Dec 2025 | 37.45k | 0.09% |
| RhumbLine Advisers LPas of 31 Dec 2025 | 11.69k | 0.03% |
| Geode Capital Management LLCas of 31 Dec 2025 | 11.57k | 0.03% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
